Background: A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks. Objective: To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations. Method: A retrospective study in 34 patients. Results: Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease. Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established. Copyright

, , ,
doi.org/10.1159/000228337, hdl.handle.net/1765/24929
Dermatology: international journal for clinical and investigative dermatology
Erasmus MC: University Medical Center Rotterdam

van der Zee, H., Boer, J., Prens, E., & Jemec, G. (2009). The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology: international journal for clinical and investigative dermatology, 219(2), 143–147. doi:10.1159/000228337